Radiology · 2017 · 38 citations · 32 references
MedicineBiochemistryBiomedical ImagingDiagnostic ImagingMolecular ImagingBiomarkers Of Liver InjuryHepatic PathologyHepatic PathophysiologyLiver DiseaseLiver ImagingMetabolic Liver DiseaseFatty Liver Disease ImagingHepatic Steatosis AssessmentHistologic ExaminationKnockout Mouse ModelsLiver Biopsy HistopathologyMagnetic ResonanceMyeloperoxidase DeficiencySteatosis Biomarkers
Purpose To test whether MPO-Gd, an activatable molecular magnetic resonance (MR) imaging agent specific for myeloperoxidase (MPO) activity, could detect MPO activity in nonalcoholic steatohepatitis (NASH) mouse models and human liver biopsy samples. Materials and Methods In this study, 20 leptin receptor–deficient and three MPO knockout mice were injected with endotoxin (lipopolysaccharide) or fed a methionine and choline–deficient (MCD) diet to induce experimental NASH and underwent MR imaging with MPO-Gd. Saline-injected and control diet–fed leptin receptor–deficient mice were used as respective controls. MPO protein and activity measurements and histologic analyses were performed. Eleven human liver biopsy samples underwent MPO-Gd–enhanced MR imaging ex vivo and subsequent histologic evaluation. Results were compared with Student t test or Mann-Whitney U test. Results With endotoxin, a significantly increased contrast-to-noise ratio (CNR) was found compared with sham (mean CNR, 1.81 [95% confidence interval {CI}: 1.53, 2.10] vs 1.02 [95% CI: 0.89, 1.14]; P = .03) at MPO-Gd MR imaging. In the diet-induced NASH model, an increased CNR was also found compared with sham mice (mean CNR, 1.33 [95% CI: 1.27, 1.40] vs 0.98 [95% CI: 0.83, 1.12]; P = .008). Conversely, CNR remained at baseline in NASH mice imaged with gadopentetate dimeglumine and in MPO knockout NASH mice with MPO-Gd, which proves specificity of MPO-Gd. Ex vivo molecular MR imaging of liver biopsy samples from NASH and control patients confirmed results from animal studies (mean CNR for NASH vs control patients, 2.61 [95% CI: 1.48, 3.74] vs 1.29 [95% CI: 1.06, 1.52]; P = .004). Conclusion MPO-Gd showed elevated MPO activity in NAFLD mouse models and human liver biopsy samples. © RSNA, 2017 Online supplemental material is available for this article. An earlier incorrect version of this article appeared online. This article was corrected on April 6, 2017.
32
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams, James Lymp, Jenny St. Sauver et al. · Gastroenterology · 2005 · 2.9K citations · Full text
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
Mattias Ekstedt, Lennart Franzén, Ulrik Mathiesen et al. · Hepatology · 2006 · 2.3K citations
The utility of radiological imaging in nonalcoholic fatty liver disease
Sherif Saadeh, Zobair M. Younossi, Erick M. Remer et al. · Gastroenterology · 2002 · 2.1K citations
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Vlad Ratziu, Frédéric Charlotte, A. Heurtier et al. · Gastroenterology · 2005 · 2.1K citations